Pilot Feasibility Study of a Sjögren's Syndrome Self-management App
NCT04653935 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 996
Last updated 2021-04-15
Summary
This study investigates the feasibility of a fully remote effectiveness evaluation of a self-management smartphone application for those with Sjogren's syndrome.
Conditions
- Sjogren's Syndrome
Interventions
- BEHAVIORAL
-
Self-management app with all intervention components
A behavioural self-management app, containing multiple cognitive- and behavioural self-management techniques for those living with Sjögren's syndrome. The intervention is comprised of several components and modules that holistically target several key symptoms: fatigue, sleep disturbances, chronic pain, and dryness. The app has been developed using user-centred methods, and is theory- and evidence-based.
- BEHAVIORAL
-
Self-management app with Information component only
self-management app for those with Sjögren's syndrome, includes Symptom and Lifestyle Information, only.
Sponsors & Collaborators
-
Newcastle University
collaborator OTHER -
Teesside University
collaborator OTHER -
Versus Arthritis
collaborator OTHER -
Northumbria University
lead OTHER
Principal Investigators
-
Katie L Hackett, PhD · Northumbria University
-
Claire H McCallum, PhD · Northumbria University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-06
- Primary Completion
- 2021-05-31
- Completion
- 2021-07-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR)
NCT06680310 ·Status: NOT_YET_RECRUITING
-
A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
NCT01689350 ·Status: COMPLETED ·Phase: NA
-
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
NCT00101829 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RSLV-132 in Females With Sjögren's Disease
NCT06440525 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
NCT05673993 ·Status: COMPLETED ·Phase: PHASE3
-
SS-INQ Information Needs Questionnaire in Sjögren's Syndrome
NCT04798911 ·Status: COMPLETED
-
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
NCT03247686 ·Status: COMPLETED ·Phase: PHASE2
-
Tolerance and Efficacy of Rituximab in Sjogren's Disease
NCT00740948 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
NCT04035668 ·Status: TERMINATED ·Phase: PHASE2
-
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949 ·Status: RECRUITING ·Phase: PHASE3
-
Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome
NCT06862284 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
NCT02701985 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099 ·Status: RECRUITING ·Phase: PHASE1
-
Study of CM355 in Patients With Systemic Lupus Erythematosus
NCT07104344 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
NCT02843659 ·Status: TERMINATED ·Phase: PHASE2
-
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
NCT00632866 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Flt3-Ligand Levels in Sjögrens Syndrome
NCT01470638 ·Status: COMPLETED
-
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
NCT04924296 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
NCT02472795 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
NCT06394063 ·Status: RECRUITING ·Phase: NA
-
Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus
NCT00004643 ·Status: COMPLETED ·Phase: PHASE2
-
The ASSESS National Multi-center Prospective Cohort
NCT03040583 ·Status: RECRUITING
-
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
NCT03003572 ·Status: RECRUITING
-
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus
NCT06955598 ·Status: COMPLETED ·Phase: PHASE1